Photobiomodulation: Innovation on the Horizon for Dry AMD. Rosen, 2024
Over the past decade, more than 30 published studies have explored the value of PBM for ocular conditions.
Photobiomodulation use in ophthalmology – an overview of translational research, Valter et al, 2024
In the past 20 years, experimental evidence has shown the benefit of PBM in increasing numbers of retinal and ophthalmic conditions. More recently, preclinical findings in ocular models have been translated to the clinic with promising results.
Is Multiwavelength PBM Effective and Safe for Age-Related Macular Degeneration? Jackson et al. 2023
This systematic review and meta-analysis compares the complications and effects of photobiomodulation (PBM) therapy with sham treatment in patients with age-related macular degeneration (AMD).
Randomized Clinical Trial of 670nm PBM for Center-Involved Diabetic Macular Edema, Kim BJ, et al. 2022
Methods: One eye of each participant was randomly assigned 1:1 to a 670-nm light-emitting PBM eye patch or an identical device emitting broad-spectrum white light at low power. Treatment was applied for 90 seconds twice daily for 4 months.
Evaluating the Effects of 670 nm Photobiomodulation in Healthy Aging and AMD, a Pilot Study. Grewal DS et al, 2020
670 nm light therapy improves rod function in normal aging but may be less effective in intermediate AMD
